Western blotting showed that the expression of ADAM17 in the high-grade (WHO III–IV; 1.292±0.140) and low-grade (WHO I–II; 0.823±0.101) glioma groups were significantly higher compared with the control brain tissue (0.325±0.068). This evidence concerns the gene ADAM17 and central nervous system cancer.